Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment

摘要

The armamentarium of oncology health-care providers was restricted to chemotherapy for decades, but today's treatment landscape is dominated by a host of novel agents, including immunotherapies, which have significantly improved outcomes for many patients, even cure for some patients with diseases once considered to be unbeatable only recently. With these new agents, however, comes a steep learning curve for health-care providers who are grappling with unfamiliar terminology and a need to understand concepts once reserved for scientists. At JADPRO Live 2019, Kris-ta M. Rubin, MS, FNF-BC, and Anthony J. Olszanski, MD, RPh, discussed the use of agents with novel mechanisms of action and toxicity profiles.